🇺🇸 FDA
Patent

US 10626372

Methods and compositions for inducing hematopoietic cell differentiation

granted A61PA61P37/02

Quick answer

US patent 10626372 (Methods and compositions for inducing hematopoietic cell differentiation) held by Fate Therapeutics, Inc. expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Fate Therapeutics, Inc.
Grant date
Tue Apr 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P37/02